Abiomed to Collaborate With Shockwave Medical
December 11, 2018 – Shockwave Medical, Inc. announced an investment and collaboration agreement with Abiomed, Inc.
Under the terms of the agreement, Abiomed will invest $15 million in Shockwave Medical and the two companies will collaborate on a training and education program in the United States and Germany focused on the benefits of complimentary use of their respective technologies.
Shockwave Medical develops and commercializes intravascular lithotripsy (IVL) technology, which treats complex calcified cardiovascular disease. The company's IVL technology employs sonic pressure waves to safely crack vascular calcium within the vessel wall, which enables arteries to expand under low pressure and become more compliant.
The Shockwave M5 peripheral IVL catheter is available in the United States and Europe for the treatment of patients with heavily calcified Iliac arteries to facilitate the transfemoral delivery of devices with catheters, including transcatheter aortic valves and Abiomed’s Impella system. In Europe, the company also markets the Shockwave C2 coronary catheter for the treatment of severely calcified de novo coronary artery disease, stated the company.